Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors

Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic innovation & regulatory science 2015-05, Vol.49 (3), p.352-358
Main Authors: Klopfenstein, Mitchell, Van Campen, Luann E., Garnett, Timothy
Format: Article
Language:English
Subjects:
Authorship
Clinical trials
Corporate sponsorship
Decision making
Drug Safety and Pharmacovigilance
Drugs
Ethics
Ethics Special Section
Ethics Special Section: Analytical Report
Pharmaceutical industry
Pharmacotherapy
Pharmacy
Regulatory approval
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c504t-eee8d75a2fa081eba3e019910aae2bf03d9a8f2b6044f85e6cf44f34bcc71bf53
cites cdi_FETCH-LOGICAL-c504t-eee8d75a2fa081eba3e019910aae2bf03d9a8f2b6044f85e6cf44f34bcc71bf53
container_end_page 358
container_issue 3
container_start_page 352
container_title Therapeutic innovation & regulatory science
container_volume 49
creator Klopfenstein, Mitchell
Van Campen, Luann E.
Garnett, Timothy
description Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval access to an investigational drug can be provided to a group of patients. Although an EAP is a regulated program, the decision to authorize an EAP is the responsibility of the biopharmaceutical sponsor. Because of the significant impact an EAP can have on current patients, drug development, and future patients, we propose that a sponsor’s decision must be based not only on regulatory criteria but also on ethical and practical considerations regarding implementation of an EAP. Such an approach will help ensure that decisions and plans uphold ethical precepts such as fairness, promoting good, and minimizing risk of harm.
doi_str_mv 10.1177/2168479015578154
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5802520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_2168479015578154</sage_id><sourcerecordid>2007984701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-eee8d75a2fa081eba3e019910aae2bf03d9a8f2b6044f85e6cf44f34bcc71bf53</originalsourceid><addsrcrecordid>eNqNkMtLAzEQxoMottTee5KCFy-rk2zSZC9CKfUBBT3oOWSzs-uWfdSkFf3vTemDWhDMJUPm932T-QgZULihVMpbRkeKywSoEFJRwU9Id_0UcQX8dFeHfof0vZ9DOIkSkqlz0mEJlzFQ6JLB9Gthmgyz4dha9H744trCmdpfkLPcVB7727tH3u6nr5PHaPb88DQZzyIrgC8jRFSZFIblBhTF1MQINEkoGIMszSHOEqNylo6A81wJHNk8FDFPrZU0zUXcI3cb38UqrTGz2CydqfTClbVx37o1pf7dacp3XbSfWihggkEwuN4auPZjhX6p69JbrCrTYLvymgHIJAQFNKBXR-i8XbkmrKdDWJRJECwOFGwo61rvHeb7z1DQ6-T1cfJBcnm4xF6wyzkAdAP40GoKdAeT_zaNthpT4D_4H1JjmFo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1681270523</pqid></control><display><type>article</type><title>Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>Klopfenstein, Mitchell ; Van Campen, Luann E. ; Garnett, Timothy</creator><creatorcontrib>Klopfenstein, Mitchell ; Van Campen, Luann E. ; Garnett, Timothy</creatorcontrib><description>Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval access to an investigational drug can be provided to a group of patients. Although an EAP is a regulated program, the decision to authorize an EAP is the responsibility of the biopharmaceutical sponsor. Because of the significant impact an EAP can have on current patients, drug development, and future patients, we propose that a sponsor’s decision must be based not only on regulatory criteria but also on ethical and practical considerations regarding implementation of an EAP. Such an approach will help ensure that decisions and plans uphold ethical precepts such as fairness, promoting good, and minimizing risk of harm.</description><identifier>ISSN: 2168-4790</identifier><identifier>EISSN: 2168-4804</identifier><identifier>DOI: 10.1177/2168479015578154</identifier><identifier>PMID: 29473010</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Authorship ; Clinical trials ; Corporate sponsorship ; Decision making ; Drug Safety and Pharmacovigilance ; Drugs ; Ethics ; Ethics Special Section ; Ethics Special Section: Analytical Report ; Pharmaceutical industry ; Pharmacotherapy ; Pharmacy ; Regulatory approval</subject><ispartof>Therapeutic innovation &amp; regulatory science, 2015-05, Vol.49 (3), p.352-358</ispartof><rights>The Author(s) 2015</rights><rights>Drug Information Association, Inc 2015</rights><rights>Copyright Drug Information Association May 2015</rights><rights>The Author(s) 2015 2015 Drug Information Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-eee8d75a2fa081eba3e019910aae2bf03d9a8f2b6044f85e6cf44f34bcc71bf53</citedby><cites>FETCH-LOGICAL-c504t-eee8d75a2fa081eba3e019910aae2bf03d9a8f2b6044f85e6cf44f34bcc71bf53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29473010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klopfenstein, Mitchell</creatorcontrib><creatorcontrib>Van Campen, Luann E.</creatorcontrib><creatorcontrib>Garnett, Timothy</creatorcontrib><title>Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors</title><title>Therapeutic innovation &amp; regulatory science</title><addtitle>Ther Innov Regul Sci</addtitle><addtitle>Ther Innov Regul Sci</addtitle><description>Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval access to an investigational drug can be provided to a group of patients. Although an EAP is a regulated program, the decision to authorize an EAP is the responsibility of the biopharmaceutical sponsor. Because of the significant impact an EAP can have on current patients, drug development, and future patients, we propose that a sponsor’s decision must be based not only on regulatory criteria but also on ethical and practical considerations regarding implementation of an EAP. Such an approach will help ensure that decisions and plans uphold ethical precepts such as fairness, promoting good, and minimizing risk of harm.</description><subject>Authorship</subject><subject>Clinical trials</subject><subject>Corporate sponsorship</subject><subject>Decision making</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Drugs</subject><subject>Ethics</subject><subject>Ethics Special Section</subject><subject>Ethics Special Section: Analytical Report</subject><subject>Pharmaceutical industry</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Regulatory approval</subject><issn>2168-4790</issn><issn>2168-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><recordid>eNqNkMtLAzEQxoMottTee5KCFy-rk2zSZC9CKfUBBT3oOWSzs-uWfdSkFf3vTemDWhDMJUPm932T-QgZULihVMpbRkeKywSoEFJRwU9Id_0UcQX8dFeHfof0vZ9DOIkSkqlz0mEJlzFQ6JLB9Gthmgyz4dha9H744trCmdpfkLPcVB7727tH3u6nr5PHaPb88DQZzyIrgC8jRFSZFIblBhTF1MQINEkoGIMszSHOEqNylo6A81wJHNk8FDFPrZU0zUXcI3cb38UqrTGz2CydqfTClbVx37o1pf7dacp3XbSfWihggkEwuN4auPZjhX6p69JbrCrTYLvymgHIJAQFNKBXR-i8XbkmrKdDWJRJECwOFGwo61rvHeb7z1DQ6-T1cfJBcnm4xF6wyzkAdAP40GoKdAeT_zaNthpT4D_4H1JjmFo</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Klopfenstein, Mitchell</creator><creator>Van Campen, Luann E.</creator><creator>Garnett, Timothy</creator><general>SAGE Publications</general><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AFRWT</scope><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150501</creationdate><title>Expanded Access Programs</title><author>Klopfenstein, Mitchell ; Van Campen, Luann E. ; Garnett, Timothy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-eee8d75a2fa081eba3e019910aae2bf03d9a8f2b6044f85e6cf44f34bcc71bf53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Authorship</topic><topic>Clinical trials</topic><topic>Corporate sponsorship</topic><topic>Decision making</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Drugs</topic><topic>Ethics</topic><topic>Ethics Special Section</topic><topic>Ethics Special Section: Analytical Report</topic><topic>Pharmaceutical industry</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Regulatory approval</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klopfenstein, Mitchell</creatorcontrib><creatorcontrib>Van Campen, Luann E.</creatorcontrib><creatorcontrib>Garnett, Timothy</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Therapeutic innovation &amp; regulatory science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klopfenstein, Mitchell</au><au>Van Campen, Luann E.</au><au>Garnett, Timothy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors</atitle><jtitle>Therapeutic innovation &amp; regulatory science</jtitle><stitle>Ther Innov Regul Sci</stitle><addtitle>Ther Innov Regul Sci</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>49</volume><issue>3</issue><spage>352</spage><epage>358</epage><pages>352-358</pages><issn>2168-4790</issn><eissn>2168-4804</eissn><abstract>Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval access to an investigational drug can be provided to a group of patients. Although an EAP is a regulated program, the decision to authorize an EAP is the responsibility of the biopharmaceutical sponsor. Because of the significant impact an EAP can have on current patients, drug development, and future patients, we propose that a sponsor’s decision must be based not only on regulatory criteria but also on ethical and practical considerations regarding implementation of an EAP. Such an approach will help ensure that decisions and plans uphold ethical precepts such as fairness, promoting good, and minimizing risk of harm.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>29473010</pmid><doi>10.1177/2168479015578154</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-4790
ispartof Therapeutic innovation & regulatory science, 2015-05, Vol.49 (3), p.352-358
issn 2168-4790
2168-4804
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5802520
source Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List
subjects Authorship
Clinical trials
Corporate sponsorship
Decision making
Drug Safety and Pharmacovigilance
Drugs
Ethics
Ethics Special Section
Ethics Special Section: Analytical Report
Pharmaceutical industry
Pharmacotherapy
Pharmacy
Regulatory approval
title Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A53%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expanded%20Access%20Programs:%20Ethical%20and%20Practical%20Considerations%20for%20Biopharmaceutical%20Sponsors&rft.jtitle=Therapeutic%20innovation%20&%20regulatory%20science&rft.au=Klopfenstein,%20Mitchell&rft.date=2015-05-01&rft.volume=49&rft.issue=3&rft.spage=352&rft.epage=358&rft.pages=352-358&rft.issn=2168-4790&rft.eissn=2168-4804&rft_id=info:doi/10.1177/2168479015578154&rft_dat=%3Cproquest_pubme%3E2007984701%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c504t-eee8d75a2fa081eba3e019910aae2bf03d9a8f2b6044f85e6cf44f34bcc71bf53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1681270523&rft_id=info:pmid/29473010&rft_sage_id=10.1177_2168479015578154&rfr_iscdi=true